This article charts over 50years of research from the discovery of the first PARP enzyme in 1963, to theapproval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza),in the treatment of BRCA-mutated ovarian cancer. The gene discussed is PARP1; the disease is ovarian carcinoma.